NCT07746232Not yet recruiting
Validating DW-MRI and Fat Fraction in Multiple Myeloma Post-ASCT: The RAC-FAT Study"
Multicenter Observational Study for the Validation of the Predictive Role of Diffusion-Weighted Whole-body MRI (DW-MRI) Imaging Response According to MY-RADS Criteria (RAC Score) and Fat Fraction (rFF%) After Autologous Stem Cell Transplantation in Multiple Myeloma Patients Treated With First-Line Anti-CD38-Based Therapy (RAC-FAT Study)
Source: ClinicalTrials.gov · Last updated 9 Sept 2026
Brief summary (registry, in English)
This is a multicenter, observational, retrospective-prospective study designed to validate the predictive role of advanced imaging in patients with newly diagnosed multiple myeloma (NDMM). The main purpose of this study is to estimate the prevalence of radiological response categories (Response Assessment Category, RAC score) and evaluate the predictive value of relative Fat Fraction (rFF%) using Diffusion-Weighted Whole-Body Magnetic Resonance Imaging (DW-MRI) in patients who have undergone autologous stem cell transplantation (ASCT) after receiving first-line anti-CD38-based quadruplet induction therapy.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 92 (estimated)
- First submitted
- 21 Jul 2026
- Start date
- 1 Oct 2026
- Primary completion date
- 31 Aug 2028
- Lead sponsor
- Fondazione EMN Italy Onlus
- Diseases
- Multiple myeloma
- NCT number
- NCT07746232
What you commit to
- Study type: Observational
- Planned participants: 92
- From 1 Oct 2026 to the primary completion date, 31 Aug 2028
- 10 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \- Absence of post-ASCT/pre-maintenance DW-MRI.
Who the study is looking for
- Newly diagnosed MM participants eligible for ASCT, treated with anti-CD38-based quadruplet induction therapy and ASCT, with post-ASCT/premaintenance DW-MRI available (in tandem ASCT, DW-MRI after second ASCT will be considered).
- Age ≥18 years.
- Participant must sign an informed consent form (ICF) that he or she understands the purpose of, and procedures required for the trial and is willing to participate in the trial.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (10)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| IRCCS Istituto Tumori "G. Paolo II - U.O.C. Ematologia e Terapia Cellulare Coordinator of this site? Confirm its status | Bari | Italy | Unknown status |
| A.O.U. di Bologna Policlinico S.Orsola Malpighi Coordinator of this site? Confirm its status | Bologna | Italy | Unknown status |
| A.O. Spedali Civili di Brescia Coordinator of this site? Confirm its status | Brescia | Italy | Unknown status |
| Istituto Oncologico Veneto IRCCS - UOC Oncoematologia Coordinator of this site? Confirm its status | Castelfranco Veneto | Italy | Unknown status |
| Ospedale Classificato Valduce Coordinator of this site? Confirm its status | Como | Italy | Unknown status |
| Ospedale Niguarda Coordinator of this site? Confirm its status | Milan | Italy | Unknown status |
| I.R.C.C.S. Ospedale S. Raffaele Coordinator of this site? Confirm its status | Milan | Italy | Unknown status |
| A.O.U. Maggiore della Carità Coordinator of this site? Confirm its status | Novara | Italy | Unknown status |
| Policlinico S. Matteo Fondazione IRCCS Coordinator of this site? Confirm its status | Pavia | Italy | Unknown status |
| ASL Roma 1 Coordinator of this site? Confirm its status | Rome | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.